Geron (NASDAQ:GERN) Stock Price Down 3.3% – Time to Sell?

Geron Co. (NASDAQ:GERN)’s share price traded down 3.3% during trading on Monday . The stock traded as low as $1.32 and last traded at $1.34. 1,223,539 shares were traded during mid-day trading, a decline of 89% from the average session volume of 11,380,408 shares. The stock had previously closed at $1.38.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Barclays restated an “overweight” rating and set a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. Scotiabank reduced their price objective on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.75.

Geron Trading Down 6.2 %

The firm has a market capitalization of $824.79 million, a PE ratio of -4.05 and a beta of 0.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company has a fifty day moving average of $1.93 and a 200-day moving average of $3.12.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. On average, sell-side analysts anticipate that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of Geron

Large investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP boosted its holdings in Geron by 947.6% in the fourth quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 9,950,000 shares in the last quarter. Braidwell LP acquired a new stake in shares of Geron in the fourth quarter worth about $24,802,000. State Street Corp boosted its stake in shares of Geron by 28.4% during the 3rd quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock worth $131,486,000 after acquiring an additional 6,413,204 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Geron in the 4th quarter valued at approximately $21,240,000. Finally, Woodline Partners LP raised its stake in shares of Geron by 64.6% in the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock valued at $41,019,000 after acquiring an additional 4,549,031 shares in the last quarter. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.